secwatch.observer — SEC 8-K summary
======================================

Issuer:     INTEGRATED BIOPHARMA INC (INBP)
CIK:        0001016504
Form:       8-K
Filed at:   2024-09-23T23:59:59+00:00
Accession:  0001437749-24-029810
Event type: earnings
Sentiment:  neutral
Materiality: 0.50
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Integrated BioPharma Q4 net income $0.3M ($0.01/share); FY net income $112K vs loss $34K
--------------------------------------------------------------------------------

- Revenue Q4 $12.7M (-2.3% YoY); FY $50.3M (-0.7% YoY).
- Operating income improved to $402K Q4 and $251K FY, from $79K and $120K prior.
- Net income Q4 $268K ($0.01 diluted) vs $40K ($0.00); FY net income $112K ($0.00) vs net loss $34K.
- Two largest customers accounted for 90% of FY2024 revenue (89% prior year).
- Co-CEOs cite focus on core businesses and new prospects to diversify customer base.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1016504/000143774924029810/0001437749-24-029810-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1016504/000143774924029810/inbp20240917_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-029810

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer